ERBB2 and breast cancer: In the future, based on these findings, further exploration may focus on modulating key ICs and signaling pathways to achieve precision immunotherapy for HER2-BC, ultimately improving patient prognosis, reducing mortality rates, and offering new hope for overcoming this refractory malignancy.